SGS, a leading bio/pharmaceutical analytical and bioanalytical contract solutions provider, is expanding its facility in Lincolnshire, in the northern suburbs of Chicago, Illinois.
The expansion will increase the site’s current footprint from 38,500 sq. ft to nearly 58,000 sq. ft. and is due to be completed by September 2017.
The expansion will allow the facility to increase capacity for the wide range of services that it offers, including analytical method development and testing, microbiological evaluation, drug stability studies, testing of containers and medical devices, and utilities qualification and monitoring. Additional staff will be employed to meet the demands on the laboratory.
“This investment allows us to be flexible in our approach to meeting both existing and future customer demands,” commented James Nokes, Vice President, US Agriculture, Food and Life.
“Analysis and bioanalysis techniques continue to evolve rapidly, and are driven by technological advances and regulatory needs. At SGS, it is our aim to ensure we can offer our clients integrated solutions to support their needs, so we continue to invest in capabilities, capacity and our staff to maintain our professionalism and efficiency.”
The expansion at SGS’s Lincolnshire site follows a series of recent investments at the company’s global laboratory network.
Increases in extractables and leachables capabilities have taken place at Fairfield (NJ, USA) and Shanghai, China, whereas French facilities at Poitiers and Villeneuve-la-Garenne have seen investment in bioanalytical capabilities and elemental analysis, respectively.
With 20 laboratories offering contract analytical and bioanalytical services, SGS leverages its wholly owned global network, present in North America, Europe, and Asia, to deliver harmonised solutions to large pharmaceutical and biotechnology firms.
In addition to testing services for the bio/pharmaceutical market, SGS also provides Phase I-IV clinical trial management, and services encompassing data management and statistics, PK/PD modelling and simulation, pharmacovigilance and regulatory consultancy.